The original document seems to suggest that the life sciences, at least as far as publication is concerned, appeared to buck the trend. > ... firms in the life

The original document seems to suggest that the life sciences, at least as far as publication is concerned, appeared to buck the trend. > ... firms in the life sciences such as Pharmacia, Lilly, Bristol Myers Squibb, Pfizer, and Amgen significantly increased publications. In the case of Pfizer and Amgen in the 2000s, this increase in publishing kept up with changes in R&D expenditures. One key feature of the pharmaceutical industry during this time period was the strong merger activity. However, comparisons with other sectors that also experienced strong merger activity suggests that the publishing behavior of firms in the life sciences was not simply an artifact of merger activity.[1] [1] https://static1.squarespace.com/static/593d9b08be65945a2e878544/t/5d31ac9b33ae9b0001d88216/1563536539717/c14259.pdf https://static1.squarespace.com/static/593d9b08be65945a2e878... Page 29